No Data
No Data
Buy Rating Affirmed for Pulmonx: Strong Growth and Promising Clinical Advancements
Pulmonx | 10-Q: Q2 2024 Earnings Report
Analysts Are Updating Their Pulmonx Corporation (NASDAQ:LUNG) Estimates After Its Second-Quarter Results
Pulmonx Is Maintained at Buy by Canaccord Genuity
Pulmonx Price Target Cut to $10.00/Share From $14.00 by Wells Fargo
Pulmonx Is Maintained at Equal-Weight by Wells Fargo
No Data